Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)

NCT00129805 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1510

Enrollment

INDUSTRY

Sponsor class

Conditions

Cerebral Infarction

Interventions

DRUG: MCI-9042
DRUG: Aspirin

Sponsor

Tanabe Pharma Corporation